The subrenal capsule assay (SRCA) is used in clinical oncology to assess the sensitivity of individual @entity5 to various anticancer agents and their combinations. Mitotic indices reflect @entity5 cell proliferation and have prognostic value in @entity2785 , including @entity43 . We combined the two tests (SRCA, mitotic index) by evaluating the numbers of mitotic figures per square millimeter of neoplastic epithelium (M/V) in @entity982 -embedded @entity5 samples after SRCA. The M/V index was compared with the @entity5 size measurement (dTS), which is used in conventional SRCA to predict the drug response. Histology examination showed insignificant changes in the size of @entity5 transplants due to host reaction but disclosed a number of potential errors in the use of dTS to evaluate transplant growth and drug effects. In our series of 62 @entity1 with advanced @entity43 the M/V value was superior to the dTS in explaining the clinical response after 6 months as assessed at second-look laparotomy. @entity1 showing no response had significantly higher M/V values than did those displaying complete or partial responses (P < 0.033). The use of 6 mitotic figures/ @entity202 as a limit differentiating responders from nonresponders resulted in an overall predictive accuracy of 79% in the logistic regression analysis. In comparison to the FIGO stage, @entity41 size, and the dTS, the M/V value obtained for the cytostatic combination given to the @entity1 was the single most significant factor predicting the 6-month clinical response. The results indicate that the combined use of the M/V index and SRCA is a promising new approach to prediction of the drug response in @entity43 .

Mitotic index in the subrenal capsule assay as an indicator of the XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian adenocarcinoma'] @entity2785 :: ('MESH:D009375', 'Disease') :: ['epithelial neoplasms'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity202 :: ('10687', 'Gene') :: ['mm2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant tumors', 'cancer'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']
@entity43 :: (MESH:D010051,Disease) :: ['chemosensitivity of ovarian cancer']
